Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment
The Australian Patent Office has granted a patent protecting a novel immunotherapeutic composition developed by Diamyd Medical for use in the treatment and prevention of autoimmune diabetes. The patent, valid until 2035, covers a composition comprising the antigens glutamic acid decarboxylase (GAD) and proinsulin immobilized on separate carrier particles.“This patent expands our precision medicine platform for autoimmune diabetes and reinforces the intellectual property protection around our immunotherapeutic technologies,” says Anton Lindqvist, Chief Scientific Officer of Diamyd Medical. “